Stock PHAT PHATHOM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
9.18 USD +0.88% Intraday chart for Phathom Pharmaceuticals, Inc. +2.34% +0.55%
Mar. 07 Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Mar. 07 Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Evolution of the average Target Price on Phathom Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9f33f8b5e847d6fd345630bb1.eJjoAnu1Cio-_mduO-XRjTKeEwxKtE4NUljPFJ0B4UI.PdeJeA-GfUEOqCJdeLaAu1X9XX8wxwtAPjmdR-xtjzJI1NBaIeBvbQmSEA~68bc257babcd36d6c19c8aa0c6f6d1ee

Analyst Recommendations on Phathom Pharmaceuticals, Inc.

Needham Raises Price Target on Phathom Pharmaceuticals to $26 From $23, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Phathom Pharmaceuticals to $10 From $9, Maintains Neutral Rating MT
HC Wainwright Initiates Coverage on Phathom Pharmaceuticals with Buy Rating, $28 Price Target MT
Craig-Hallum Starts Phathom Pharmaceuticals at Buy With $21 Price Target MT
BMO Capital Adjusts Price Target on Phathom Pharmaceuticals to $30 From $35, Maintains Outperform Rating MT
Needham Adjusts Price Target on Phathom Pharmaceuticals to $23 From $25, Maintains Buy Rating MT
BMO Capital Trims Price Target on Phathom Pharmaceuticals to $35 From $38, Affirms Outperform Rating MT
Needham Adjusts Phathom Pharmaceuticals Price Target to $25 From $38, Maintains Buy Rating MT
BMO Capital Cuts Price Target on Phathom Pharmaceuticals to $38 From $45, Maintains Outperform Rating MT
Guggenheim Adjusts Price Target on Phathom Pharmaceuticals to $30 From $42, Maintains Buy Rating MT
Jefferies Starts Phathom Pharmaceuticals at Buy With $16 Price Target MT
Needham Adjusts Phathom Pharmaceuticals' Price Target to $38 from $44, Keeps Buy Rating MT
Goldman Sachs Adjusts Price Target for Phathom Pharmaceuticals to $15 From $32, Retains Neutral Rating MT
PHATHOM PHARMACEUTICALS : Guggenheim Adjusts Phathom Pharmaceuticals PT to $75 From $66, Maintains Buy Rating MT
PHATHOM PHARMACEUTICALS : Goldman Sachs Upgrades Phathom Pharmaceuticals to Neutral From Sell, Adjusts Price Target to $48 From $40 MT
PHATHOM PHARMACEUTICALS : BMO Capital Starts Phathom Pharmaceuticals at Outperform With $63 Price Target MT
PHATHOM PHARMACEUTICALS : Guggenheim Starts Phathom Pharmaceuticals at Buy With $60 Price Target MT
PHATHOM PHARMACEUTICALS : Needham Adjusts Phathom Pharmaceuticals' Price Target to $55 from $45, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.18 USD
Average target price
22 USD
Spread / Average Target
+139.65%
High Price Target
28 USD
Spread / Highest target
+205.01%
Low Price Target
10 USD
Spread / Lowest Target
+8.93%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Phathom Pharmaceuticals, Inc.

Needham & Co.
Goldman Sachs
HC Wainwright
Craig-Hallum
BMO Capital
Guggenheim
Jefferies & Co.

Ratings for Phathom Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PHAT Stock
  4. Consensus Phathom Pharmaceuticals, Inc.